Company Profile
ImmuPharma provides the research, development, and commercialization of peptide-based therapeutics for autoimmune diseases, infectious diseases, and metabolic disorders in the United Kingdom and globally.
It develops P140, a peptide-based therapy, which is in clinical trial for the treatment of autoimmune and inflammatory diseases, as well as various therapeutic areas including dermatology, gastroenterology, rheumatology, endocrinology, and neurology
CDx, a companion diagnostic, which is in clinical trial for the identification of immune endotype and treatment of various autoimmune diseases. The company is also involved in the development of Kapiglucagon, a proprietary glucagon prodrug, which is in pre-clinical trial for the treatment of type 1 diabetes.
Its portfolio also includes BioAMB, an amphotericin-B therapy, which is in pre-clinical trial for the treatment of invasive fungal infections, such as aspergillosis, and BioCIN, a vancomycin-based therapy, which is in pre-clinical trial for the treatment of gram-positive infections comprising methicillin-resistant staphylococcus aureus, sepsis, lower respiratory tract infections, osteomyelitis, and skin infections.
It has collaboration arrangements with Avion Pharmaceuticals LLC and Centre National de la Recherche Scientifique for the development of P140 platform. Founded in 1999, the company is headquartered in London, the United Kingdom.